
Claims

1. A dry pharmaceutical formulation, wherein the pharmaceutical formulation comprises a CNP conjugate, a buffering agent, a bulking agent and a pH-adjusting agent, wherein the CNP conjugate comprises a CNP moiety that is covalently and reversibly conjugated to a polymeric moiety, the buffering agent is succinic acid, the bulking agent is trehalose dihydrate and the pH-adjusting agent is Tris, and wherein the formulation comprises based on the total weight of the dry pharmaceutical formulation:

CNP conjugate	1.3 - 45.4 % (w/w)
succinic acid	0.2 - 3.2 % (w/w)
trehalose dihydrate	52.6 - 98.4 % (w/w)
Tris	0.1 - 5.6 % (w/w);

wherein the CNP conjugate is of formula (IIf):




(IIf),

wherein

the unmarked dashed line indicates the attachment to a nitrogen of a CNP moiety by forming an amide bond, wherein the CNP moiety has the sequence of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 or SEQ ID NO:30; and


the dashed line marked with the asterisk indicates attachment to the following structure



,

wherein

each -Z^a is



and wherein


each c1 is an integer independently ranging from 200 to 250.

2. The dry pharmaceutical formulation of claim 1, wherein the formulation comprises based on the total weight of the dry pharmaceutical formulation:

CNP conjugate	1.3 - 38.7 % (w/w)
succinic acid	0.2 - 3.2 % (w/w)
trehalose dihydrate	52.6 - 98.4 % (w/w)
Tris	0.1 - 5.6 % (w/w).

3. The dry pharmaceutical formulation of claim 1 or 2, wherein the CNP moiety has the sequence of SEQ ID NO:24.

4. The dry pharmaceutical formulation of any one of claims 1 to 3, wherein the CNP conjugate is of formula (IIf ’):




(IIf ’),

wherein

the unmarked dashed line indicates the attachment to a nitrogen provided by the side chain of the lysine at position 26 of the CNP moiety of SEQ ID NO:24 by forming an amide bond; and


the dashed line marked with the asterisk indicates attachment to the following structure



,

wherein


each -Z^a is



and wherein

each c1 is an integer independently ranging from 200 to 250.

5. The dry pharmaceutical formulation of any one of claims 1 to 4, wherein the CNP conjugate has the following structure




,

wherein

the unmarked dashed line indicates the attachment to a nitrogen provided by the side chain of the lysine at position 26 of a CNP moiety of SEQ ID NO:24 by forming an amide bond; and


the dashed line marked with the asterisk indicates attachment to the following structure



(h-i),

wherein

each -Z^c is a moiety



,

and wherein

each c1 is an integer independently ranging from 200 to 250.